Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Apr 19;2012(2):87-98.
doi: 10.2147/BLCTT.S18701.

Treatment Strategies for Patients with Diffuse Large B-Cell Lymphoma: Past, Present, and Future

Rajni Sinha  1 , Loretta Nastoupil, Christopher R Flowers
Affiliations

Treatment Strategies for Patients with Diffuse Large B-Cell Lymphoma: Past, Present, and Future

Rajni Sinha et al. Blood Lymphat Cancer. .

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most commonly occurring lymphoma in the Western world. DLBCL is a clinically, biologically, and pathologically heterogeneous entity with biologically distinct subtypes that have different expected treatment outcomes. The addition of rituximab to combination chemotherapy has improved outcomes for all patients with DLBCL and can produce cure for many individuals. Relapsed DLBCL is generally managed with salvage chemo-immunotherapy followed by high dose therapy and autologous stem cell transplantation which can cure additional patients. However, outcomes for patients who relapse early after upfront rituximab and chemotherapy have a poorer prognosis. Novel therapies and strategies are desperately needed for these patients and several emerging treatments hold promise for improving DLBCL treatment outcomes in the future.

Keywords: Diffuse Large B-Cell Lymphoma; Lymphoma; Non-Hodgkin Lymphoma; chemoimmunotherapy; rituximab; treatment.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST DISCLOSURES

Dr. Sinha receives research funding from Celgene Corporation. Dr. Flowers serves as a consultant to Celgene Corporation, Seattle Genetics, and Spectrum and as an unpaid consultant to Genentech and Millennium. Dr. Flowers receives research funding from Millennium Pharmaceuticals, Calistoga Pharmaceuticals, Pfizer, Novartis, and Spectrum Pharmaceuticals.

References

    1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212–236. - PubMed
    1. Abouyabis A, Shenoy P, Lechowicz M, Flowers C. Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States. Leuk Lymphoma. 2008;49(11):2099–2107. - PubMed
    1. Shenoy P, Maggioncalda A, Malik N, Flowers CR. Incidence patterns and outcomes for hodgkin lymphoma patients in the United States. Adv Hematol. 2011;2011:725219. - PMC - PubMed
    1. Shenoy PJ, Malik N, Nooka A, Sinha R, Ward KC, Brawley OW, et al. Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Cancer. 2010 - PubMed
    1. Malik N, Shenoy PJ, Bumpers K, Sinha R, Flowers CR. Racial Differences in the Presentation and Outcomes of Diffuse Large B-Cell Lymphoma in the United States. Blood (ASH Annual Meeting Abstracts) 2009;114(22) Abstract#898.